High blood pressure (HBP) is common in diabetic patients and significantly increases complications of diabetes and cardiovascular risk. It is therefore particularly important to routinely screen and treat HBP in these patients. Blood pressure targets in this population (<130/80mmHg) should be adapted to age and comorbidities. The therapeutic strategy has expanded beyond renin-angiotensin-aldosterone system inhibitors in the diabetic population, with treatments which decrease cardiovascular and renal risk, such as SGLT2 inhibitors, GLP-1 receptor agonists, and soon finerenone.